Preclinical News and Research

RSS

Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer.

24 Nov 2008

Researchers study effect of ADHD on smoking cessation

Tobacco use is more prevalent and smoking cessation less likely among persons with Attention Deficit Hyperactivity Disorder (ADHD).

21 Nov 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

KAI Pharmaceuticals reports positive results for KAI-1678 in pain reduction

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.

19 Nov 2008

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).

19 Nov 2008

Early-onset familial Alzheimer disease provides clues to treatment of common Alzheimer's

The rarest kind of Alzheimer Disease (AD) - the form that transmits from parent to child with a cruel 50 percent likelihood - has been valued for its potential to shed light for the millions of people affected by the common form of AD.

16 Nov 2008

Phosphagenics' diclofenac enters trial phase in humans

Phosphagenics Limited ("Phosphagenics") announced today that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac.

12 Nov 2008

Intraspinal implant of mesenchymal stem cells may not heal the demyelinated spinal cord

Multiple sclerosis is a disease caused by the loss of the myelinated sheath surrounding the nerve fibers of the spinal cord.

12 Nov 2008

Taking calcium and vitamin D supplements does not reduce breast cancer risk

Taking calcium and vitamin D supplements does not reduce breast cancer incidence in postmenopausal women, according to data from a randomized, doubled-blind, placebo-controlled trial published online November 11 in the Journal of the National Cancer Institute.

11 Nov 2008

Researchers test whether cocktail of vitamins and magnesium help prevent hearing loss

About 10 million people in the United States alone—from troops returning from war to students with music blasting through headphones—are suffering from impairing noise-induced hearing loss.

10 Nov 2008

Ewing sarcoma treatment ineffective, despite promising laboratory data

Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults.

10 Nov 2008

Can vitamins and minerals prevent hearing loss?

About 10 million people in the United States alone--from troops returning from war to students with music blasting through headphones--are suffering from impairing noise-induced hearing loss.

10 Nov 2008

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

T-cell-based strategy for HIV-1 vaccines still viable option

The question of whether or not to continue to pursue the development of T-cell-based HIV-1 vaccines has been a source of controversy following last year's widely publicized failure of the field's most promising candidate, a vaccine developed by Merck known as V520.

10 Nov 2008

Alteration of a gene causes neuroblastoma

Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children-neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma.

7 Nov 2008

Genentech submits application to FDA for Avastin in the most aggressive form of brain cancer

Genentech has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical benefit.

3 Nov 2008

Preclinical News and Research

Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

Researchers study effect of ADHD on smoking cessation

FDA approves GSK's Promacta (Eltrombopag)

KAI Pharmaceuticals reports positive results for KAI-1678 in pain reduction

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

Early-onset familial Alzheimer disease provides clues to treatment of common Alzheimer's

Phosphagenics' diclofenac enters trial phase in humans

Intraspinal implant of mesenchymal stem cells may not heal the demyelinated spinal cord

Taking calcium and vitamin D supplements does not reduce breast cancer risk

Researchers test whether cocktail of vitamins and magnesium help prevent hearing loss

Ewing sarcoma treatment ineffective, despite promising laboratory data

Can vitamins and minerals prevent hearing loss?

Santaris Pharma releases positive data on LNA-based survivin inhibitor

T-cell-based strategy for HIV-1 vaccines still viable option

Alteration of a gene causes neuroblastoma

Genentech submits application to FDA for Avastin in the most aggressive form of brain cancer

Pulsed ultrasound used to remote control brain circuits

Memory Pharmaceuticals issued key U.S. patent for series of nicotinic alpha-7 receptor agonists

Targanta Therapeutics presents preclinical data on Oritavancin against Clostridium difficile infection

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News